StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
CRRX.TO$3.18-2.15%
Fair $3.18+0.0%

CRRX.TO

CareRx Corporation

Healthcare / Medical Care FacilitiesToronto

$3.18

-0.07 (-2.15%)

Fairly Valued+0.0%Fair Value $3.18Fund rank 28/100 · Data gapFallback financials|
SA 34/D
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $22.5M · quality 55.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 49/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · CRRX.TOLocal privado en este navegador · CareRx Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$202M

P/E

7.4x

↓

EV/EBITDA

9.4x

↓

ROE

23.9%

↑

Gross Margin

30.0%

↓

Debt/Equity

0.71

↑
52-Week Range$3
$3$4

TradingView lightweight chart

CRRX.TO price, volumen y niveles de valoración

Último $3.180Periodo -61.2%
Fair value: $3.180

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-1.0%

FCF CAGR

+37.2%

FCF margin

6.1%

FCF / Net income

0.86x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $370.2M · net income $26.1M · FCF $22.5M

2022-FY → 2025-FY

Gross margin

30.0%+1.2% pts

Operating margin

3.2%+1.2% pts

Net margin

7.1%+16.1% pts

FCF margin

6.1%+3.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$370.2M$370.2M$366.7M$370.7M$381.7M
Net Income$26.1M$26.1M$-4.5M$-5.4M$-34.4M
EBITDA$28.5M$28.5M$23.9M$24.7M$-610000.00
EPS0.410.41-0.07-0.09-0.72
Gross Margin30.0%30.0%29.5%28.2%28.8%
Operating Margin3.2%3.2%2.0%1.9%2.0%
Net Margin7.1%7.1%-1.2%-1.5%-9.0%
Balance Sheet
Debt/Equity0.710.710.981.202.10
Current Ratio1.101.10———
Cash Flow
Free Cash Flow$22.5M$22.5M$29.9M$18.7M$8.7M
Returns
ROE23.9%23.9%-5.3%-6.6%-53.3%
Valuation
P/E7.407.40———
EV/EBITDA9.439.438.407.83—
P/B1.871.871.511.252.22
Growth & Yield
Revenue Growth1.0%1.0%-1.1%-2.9%—
EPS Growth685.7%685.7%22.2%87.5%—
Dividend Yield2.5%2.5%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-11.7%

fácil

EPS terminal req.

$0.28

Spread vs growth

697.4%

5Y implied EPS CAGR

-3.6%

fácil

EPS terminal req.

$0.34

Spread vs growth

689.3%

10Y implied EPS CAGR

3.0%

fácil

EPS terminal req.

$0.55

Spread vs growth

682.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +19.4%

Total return

+19.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.07 → 0.41

Residual

+16.9%

EPS growthn/d
Multiple reratingn/d
Dividend+2.5%
Residual / FX / buybacks / cross-term+16.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.